Content available at: <https://www.ipinnovative.com/open-access-journals>

Indian Journal of Clinical Anaesthesia

Journal homepage: www.ijca.in

Original Research Article

Perioperative effect of dexmedetomidine on quality of analgesia and hemodynamic parameters in vaginal hysterectomy: A tertiary centre experience

Nishit Sud^{1,*}, Sunil Sinha²¹Dept. of Anaesthesia and Intensive Care, Guys and St. Thomas Hospital, London, England²Dept. of Anaesthesia, Lady Hardinge Medical College, New Delhi, India

ARTICLE INFO

Article history:

Received 28-07-2021

Accepted 07-08-2021

Available online 11-11-2021

Keywords:

Dexmedetomidine

Bupivacaine

Modified Ramsay sedation score

ABSTRACT

Introduction: Vaginal hysterectomy Surgery with long acting local anaesthetic like bupivacaine still requires higher doses of analgesics in the post-operative period. Dexmedetomidine is highly selective α_2 adrenoreceptor agonist and sympatholytic drug is a useful adjunct drug in patients undergoing vaginal hysterectomy under continuous spinal epidural block (CSE). We sought to study duration of perioperative analgesia, observe the intra-operative and post-operative hemodynamic changes and post-operative sedation effect of dexmedetomidine.

Materials and Methods: The study groups were divided as Group D (study group) administered 1 $\mu\text{g/kg}$ Dexmedetomidine and Group C (control group) administered 0.9% saline drip at the rate of 1ml/kg.

Results: Dexmedetomidine group had prolonged duration of sensory blockade, duration for 2 dermatomal regression of sensory blockade and the duration for motor block regression to Modified Bromage scale 0. This group had prolonged duration of Time to first request for rescue analgesic. 14% patients required mephentermine for management of hypotension.

Intraoperative diastolic blood pressure (DBP) was lower in study group while Intraoperative Systolic blood pressure (SBP) was comparable in both the groups.

Conclusions: Intravenous dexmedetomidine significantly decreases the heart rate and is associated with higher incidence of bradycardia. It is effective in providing postoperative analgesia and in preventing postoperative shivering with reduced incidence of postoperative nausea and vomiting.

This is an Open Access (OA) journal, and articles are distributed under the terms of the [Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License](https://creativecommons.org/licenses/by-nc-sa/4.0/), which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: reprint@ipinnovative.com

1. Introduction

Spinal anaesthesia is a commonly used technique in anaesthetic practice for gynaecological, lower abdominal, pelvic, and lower limb surgeries. Bupivacaine, a long acting amide is appropriate for procedures lasting for 2 to 2.5 hours. Intravenous agents epinephrine, phenylephrine, adenosine, magnesium sulphate, neostigmine and α_2 agonists like clonidine and dexmedetomidine can be used to prolong duration of surgery.¹

Dexmedetomidine is a highly selective α_2 adrenoreceptor agonist. Analgesic effect at spinal level is produced by stimulation of α_2 receptors at the substantia gelatinosa of the dorsal horn which leads to inhibition of the firing of nociceptive neurons and inhibition of the release of substance P while at supraspinal level it inhibits the release of norepinephrine and its associated activity in the descending medullospinal noradrenergic pathway secondary to activation of central α_2 receptors.² α_2 receptors affinity leads to hypnotic and analgesic effect. Sedation is produced due to suppression of neuronal firing in the locus coeruleus of the brainstem.³

* Corresponding author.

E-mail address: nsud87@gmail.com (N. Sud).

Dexmedetomidine has 8-10 times higher affinity for α_2 adrenergic receptors with selective affinity of α_2 receptors (1600: 1) which is more as compared to clonidine. It has short onset of action and peak is achieved within 15 min. High first pass metabolism leads to poor oral bioavailability. Biotransformation occurs in the liver by N-glucuronidation & CYP-450 mediated hydroxylation into inactive metabolites. These inactive metabolites are excreted in urine (about 95%) and in feces (about 5%).^{3,4}

Dexmedetomidine is used for sedation like during awake Fiberoptic intubation in difficult airway and pediatric MRI. It is also used as premedication since it reduces the hemodynamic response during intubation and extubation and as antishivering agent. Dexmedetomidine helps in treating withdrawal symptoms of benzodiazepines, alcohol and opioids.⁵

2. Materials and Methods

The prospective study was carried out in the department of anaesthesia at a tertiary care hospital in North India and included 100 adult female ASA grade I/II patients undergoing vaginal hysterectomy surgeries under bupivacaine spinal anaesthesia from November 2012 to March 2014. The study was a randomised blind trial in which patients were divided in 2 Groups to compare effect of dexmedetomidine with control group. Baseline observation (HR, BP, SpO₂, ECG) were recorded on arrival of patient in OT and epidural catheter was inserted using Touhy's needle following which patient were subsequently administered spinal anesthesia with 2.5 ml Hyperbaric Bupivacaine (5%) and 25 μ g Fentanyl intrathecally. subsequently epidural catheter was inserted into epidural space via Touhy's needle.

Adult females of 35-65 age group with ASA grade I/II were included in the study and patients on α_2 adrenergic antagonist, calcium channel blocker and ACE inhibitor, known hypersensitivity to any drugs, history of arrhythmias and heart block were excluded from study.

To detect a difference assuming a large effect (using the results of pilot studies) in the mean duration of analgesia between any two groups with $\alpha=0.05$ and power = 80% minimal sample size in each group were taken as fifty (50) assuming the dropout rate/protocol violation as 10%.

The study groups were divided as Group D (study group) administered 1 μ g/kg Dexmedetomidine given IV over 10 minutes after CSE followed by IV Dexmedetomidine 0.5 μ g/kg/hour infusion till the end of surgery and Group C (control group) administered 0.9% saline drip at the rate of 1ml/kg over 10 min followed by 0.5 ml/kg/hour till the end of surgery.

Modified Ramsay sedation scale was used to assess the level of sedation and Intraoperative pain/discomfort of patient was treated with 10 ml of 0.25% Bupivacaine via epidural catheter along with measurement of time and level

of sensory block.

Intraoperatively baseline parameters were measured in both groups initially at 5 min interval for 30 min then every 10 mins till the end of surgery. Sensory level block was assessed by using pin prick sensation with 23 G hypodermic needle in mid clavicular line bilaterally along with time taken to reach the highest sensory level and time for two dermatomal progressions. Motor blockade was assessed by Modified Bromage Scale. Time taken for motor blockade to reach Modified Bromage Scale 3 and regression of motor blockade to Modified Bromage Scale 0 was noted. Surgery was allowed to start after reaching dermatomal level of T10 Hemodynamic parameter of Hypotension was defined as decrease in systolic blood pressure by 30% from baseline or systolic blood pressure lower than 90 mm of Hg, treated with 6 mg of Intravenous mephentermine and a bolus of 250 ml of ringers lactate solution over 10 min while bradycardia was defined as Heart Rate <50 beats /min treated with 0.6 mg of Intravenous atropine.

Required approval from institutional ethical committee of University was taken. Informed written consent after detailed preanaesthetic check-up was taken. The data was compiled, tabulated and statistically analyzed using SPSS version 13. Student t test was used for analysis of continuous variables like duration of analgesia, haemodynamic parameters and Categorical variables of sedation score were expressed as frequencies and percentage and nominal categorical data between the groups were compared using chi-squared test. Results were presented as mean $\pm$ SD In all statistical tests, a p-value < 0.500 was considered significant.

3. Results

There was no significant difference between the two groups with respect to demographic data although mean age and weight were observed to be more in Dexmedetomidine group but mean height of the patients was observed to be more in control group.

Mean weight was more while height was less in the Dexmedetomidine group. The mean duration of surgery in the dexmedetomidine group was 140.9 $\pm$ 33.4 minutes as compared to 137.2 $\pm$ 33.1 minutes in control group.

3.1. Sensory and motor block

Dexmedetomidine group had prolonged duration of sensory blockade, duration for 2 dermatomal regression of sensory blockade and the duration for motor block regression to Modified Bromage scale 0. The highest level of sensory blockade, time for attaining the highest level of sensory blockade and time taken for motor blockade to reach Modified Bromage Scale 3 were comparable between both the groups.

Table 1:

	Group D	Group C	P Value
Highest Level of sensory block [dorsal]	T 6.6 ± 1	T 6.8 ± 0.8	0.272
Time for attaining highest level of sensory block	10.4 ± 1.9 mins	10.9 ± 1.7 mins	0.169
Duration for 2 Dermatomal regression of Sensory blockade	142.4 ± 10.6 mins	105.6 ± 14.4 mins	<0.001
Duration of Sensory Blockade	282.4 ± 20.2 mins	170.4 ± 12.8 mins	< 0.001
Duration for motor Blockade to reach modified Bromage Scale 3	5.12 ± 1.4 mins	4.98 ± 1.7 mins	0.654
Duration for motor block regression to Modified Bromage scale 0	232.6 ± 16.8 mins	139.4 ± 11.2 mins	<0.001

3.2. Analgesic effect

Modified Ramsay sedation scale was used to assess the level of sedation. Intraoperative pain/discomfort of patient was treated with 10 ml of 0.25% Bupivacaine via epidural catheter along with measurement of time and level of sensory block.

Dexmedetomidine group had prolonged duration of Time to first request for rescue analgesic on comparison with control group and it was statistically significant.

Ramsay sedation score were comparable in both groups at baseline level but intraoperative scores were higher in dexmedetomidine group with 46 % patients achieving a score of more than 4. Sedation scores varied over 2-3 with a mean of 2.09 in the control group. Postoperative period had no significant difference in scores of both the groups

Fig. 1: Line diagram comparing the baseline, intraoperative and postoperative (PO) Ramsay sedation scores

3.3. Hemodynamic monitoring

The hemodynamic parameters of heart rate, blood pressure (systolic, diastolic, mean) along with hemodynamic complications like hypotension, bradycardia were compared in each group and between both the groups before CSE block, at regular intervals after CSE block, till 30 mins after

completion of surgery.

There was significant decrease in the heart rate in both the groups as compared to baseline values although average intraoperative heart rate was significantly lower with 30% of patients having transient intraoperative heart rate <50/min in Dexmedetomidine group. Postoperative heart rate was significantly lower in dexmedetomidine group (59.1±5) as compared to control group (71.9±4.4) which also achieved statistical significance.

Fig. 2: Bar diagram comparing the heart rates within the groups

30% patients in dexmedetomidine group had transient intraoperative heart rate <50/min while only 4 % patients had bradycardia in control group.

Bradycardia was observed as significantly lower in dexmedetomidine group on comparison with control group.

Intraoperative Systolic blood pressure (SBP) was comparable in both the groups but the postoperative Systolic blood pressure was significantly lower in dexmedetomidine group and achieved statistical significance.

Intraoperative diastolic blood pressure (DBP) was lower in dexmedetomidine group (68.3±7.8) as compared to control group (71.5±4.6) but the postoperative Diastolic blood pressure was significantly lower in dexmedetomidine group.

14% patients required mephentermine for management of hypotension (<90mmHg or >30% fall) while only 8% patients required this drug in control group.

There was significant decrease in the mean arterial pressure in both the groups as compared to baseline

values. Intraoperative mean arterial pressure (MAP) after spinal block was comparable in both the groups. The postoperative mean arterial pressure was significantly lower in dexmedetomidine group [80.8 ± 8.1] as compared to control group [88.5 ± 5].

Respiratory rates and oxygen saturation were comparable in both the groups during surgery and in postoperative duration. 10% of control group patients showed post operative shivering while 4% patients in dexmedetomidine group had post operative nausea and vomiting.

Fig. 3: Line diagram comparing the baseline and intraoperative systolic BP

Fig. 4: Bar diagram comparing the diastolic BP within the groups

4. Discussion

Spinal anesthesia was introduced for the first time by August Bier in 1899 by using the technique of Quincke. Cocaine was used to produce the effect in the initial years.⁶

We performed this study to evaluate the effect of the duration of perioperative analgesia by adding intravenous dexmedetomidine to subarachnoid hyperbaric bupivacaine and fentanyl, to observe the intra-operative and post

operative hemodynamic changes in two groups, correlate the intra-operative and post-operative sedation effect of dexmedetomidine (using modified Ramsey scale), observe highest sensory level achieved along with time taken for sensory block to regress to T10 dermatomal level.

Minimal sample size required under each group was fifty (50) assuming the dropout rate/protocol violation as 10%.

Dexmedetomidine resulted in significant decrease in heart rate, mean arterial/systolic/diastolic blood pressures. Our findings are in agreement to the previous studies of Al Mustafa et al.,⁷ Tekin et al.⁸ who also reported a significant decrease in heart rate in dexmedetomidine group. Tekin et al.⁸ observed mean heart rate was significantly lower in dexmedetomidine group similar to our findings.

Bradycardia was observed as significantly lower in dexmedetomidine group (30% patients) on comparison with control group, which was consistent with findings of Whizar-Lugo et al.⁹ (32% patients) and Hong et al.¹⁰ (24% patients). Bradycardia caused by intravenous dexmedetomidine was without significant clinical impact and managed with atropine.

Hypotension following intravenous Dexmedetomidine was in our study (14%) had similar comparison to study of Elcicek et al.¹¹ who reported use of vasoconstrictors in 16% of patients which was treated with mephentermine.

Intraoperative mean arterial pressure (MAP) after spinal block was comparable in both the groups in our study, Al Mustafa et al.⁷ and Tekin et al.⁸ also reported no significant difference in MAP between dexmedetomidine group vs control group.

In our study, respiratory rates and oxygen saturation were comparable in both the groups during surgery and in postoperative duration which was consistent with findings of Al Mustafa et al.⁷ and Kaya et al.,¹² Similar results were reported by Elcicek et al.¹¹ Despite providing good sedation, dexmedetomidine does not cause significant respiratory

Dexmedetomidine is effective in providing postoperative analgesia in our study, Hong et al.¹⁰ had noticed that post-operative pain intensity was lower and the mean time to first request for post-operative analgesia was longer in the dexmedetomidine group, similar results were reported by Whizar-Lugo et al.⁹ regarding time for request of first dose of analgesic.

In our study, none of the patients in dexmedetomidine group had postoperative shivering as compared to 10% in control group (P value 0.056). Similar results were reported by Tekin et al.⁸ and Elcicek et al.¹¹ (0% vs 30% in dexmedetomidine and control groups respectively).

The incidence of nausea and vomiting in our study was 4% (2 patients) in dexmedetomidine group and similar incidence was reported by Tekin et al.⁸ (6.7% in dexmedetomidine group).

Our findings are in agreement to the previous studies of Tekin et al.,⁸ Whizar-Lugo et al.,⁹ Elcicek et al.¹¹ regarding the time required for attaining the highest level of sensory block was comparable in dexmedetomidine and control groups. In our study the highest level of sensory block achieved was comparable in dexmedetomidine group compared to control group, Tekin et al.,⁸ Whizar-Lugo et al.⁹ also reported similar results.

Mean time for two dermatomal regression of sensory blockade was significantly prolonged in dexmedetomidine group which was also reported by Tekin et al.,⁸ Kaya et al.¹² and Hong¹⁰ et al. Similar to our findings Al Mustafa et al.⁷ reported significant prolongation in mean duration of sensory blockade in dexmedetomidine group.

Our study showed no significant difference in time taken for motor blockade to reach modified Bromage Scale 3 in both the groups. The regression time to reach the modified Bromage Scale 0 was significantly prolonged in dexmedetomidine group, Tekin et al.⁸ and Elcicek et al.¹¹ also reported delay in motor block regression to Bromage Scale 0.

5. Conclusion

Dexmedetomidine is new generation highly selective alpha-2 adrenergic receptor agonist which is extremely effective in prolonging the duration of motor and spinal blockade after bupivacaine spinal anaesthesia. Dexmedetomidine is a more suitable adjuvant to spinal anaesthesia compared to clonidine as it has more sedative and analgesic effects due to its more selective alpha 2A receptor agonist activity. It provides good sedation during surgery which quickly reverses after stopping the drug. The sedative action of dexmedetomidine is due to suppression of neuronal firing in the locus coeruleus of the brainstem and analgesic action is mediated by supraspinal and spinal site of action. Opioid sparing effect of Dexmedetomidine makes it useful adjunct in acute and chronic painful conditions.

Intravenous dexmedetomidine significantly decreases the heart rate and is associated with higher incidence of bradycardia due to pharmacological actions of decrease in sympathetic outflow and decreased circulating levels of catecholamines.^{13,14}

Dexmedetomidine is effective in providing postoperative analgesia and in preventing postoperative shivering. It helps to prolong the time for request of first dose of analgesic. Incidence of postoperative nausea and vomiting was quite low with this drug. Dexmedetomidine acts by inhibition of central thermoregulation and attenuation of hyper adrenergic response to perioperative stress are known to prevent postoperative shivering.¹⁵

Sedation produced by dexmedetomidine mimicks natural sleep, patient remains co-operative and does not produce respiratory depression unlike benzodiazepines, thus maintaining normal SpO₂.¹⁶

Dexmedetomidine is a useful sympatholytic drug sympatholytic effect due to central α_2 A receptor, thereby blunting the hemodynamic response to tracheal intubation, extubation as well as surgical stress response.

Dexmedetomidine is a useful adjunct drug in patients undergoing vaginal hysterectomy under continuous spinal epidural block (CSE).

Vaginal hysterectomy Surgery with long acting local anaesthetic like bupivacaine still requires higher doses of analgesics in the post-operative period. Opioids are commonly used as adjuvants to intrathecal local anaesthetics but they are associated with many side effects. Our results point to the need for a more newer additives to local anaesthetics through both intravenous and intrathecal route for being investigated in an effort to increase the duration of post operative analgesia and to evaluate the potential prognostic significance of these drugs.

6. Source of Funding

No funding was received for this study.

7. Conflict of Interest

The authors declared no conflicts of interest.

References

1. Kanazi GE, Aouad MT, Jabbour-Khoury SI, Jazsar MA, Alameddine MM, Al-Yaman R, et al. Effects of low dose dexmedetomidine or clonidine on the characteristics of bupivacaine spinal block. *Acta Anaesthesiol Scand*. 2006;50:222–7.
2. Fukushima K, Nishimi Y, Mori K, Takeda J. Effect of epidurally administered dexmedetomidine on sympathetic activity and postoperative pain in man. *Anaesth Analg*. 1996;82:S121.
3. Gertler R, Brown HC, Mitchell DH, Silvius EN. Dexmedetomidine: a novel sedative- analgesic agent. *BUMC Proc*. 2001;14:13–21.
4. Barash PG, Cullen BF, Stoelting RK, Cahalan MK, Stock MC. *Clinical Anesthesia*. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2009. p. 354–5.
5. Halaszynski TM. Dexmedetomidine: A look at a promising new avenue of use. *Saudi J Anaesth*. 2012;6(2):104–6.
6. Brown DL. 1999.
7. Al-Mustafa M, Badran IZ, Abu-Ali HM, Al-Barazangi BA, Massad IM, Al-Ghanem SM. Intravenous dexmedetomidine prolongs bupivacaine spinal analgesia. *Middle East J Anaesthesiol*. 2009;20(2):225–31.
8. Tekin M, Kati I, Tomak Y, Kisli E. Effect of dexmedetomidine IV on the duration of spinal anesthesia with Prilocaine: a double- blind, prospective study in adult surgical patients. *Curr Ther Res Clin Exp*. 2007;68(5):313–24.
9. Whizar-Lugo V, Gómez-Ramírez IA, Cisneros-Corral R, Martínez-Gallegos N. Intravenous dexmedetomidine vs. intravenous clonidine to prolong bupivacaine spinal anaesthesia. A double blind study. *Anestesia en Mexico*. 2007;19:143–6.
10. Hong JY, Kim WO, Yoon Y, Choi Y, Kim SH, Kil HK. Effects of intravenous dexmedetomidine on low-dose bupivacaine spinal anaesthesia in elderly patients. *Acta Anaesthesiol Scand*. 2012;56:382–7.
11. Elcicek K, Tekin M, Kati I. The effects of intravenous dexmedetomidine on spinal hyperbaric ropivacaine anesthesia. *J Anesth*. 2010;24:544–8.
12. Kaya FN, Yavascaoglu B, Turker G, Yildirim A, Gurbet A, Mogol EB, et al. Intravenous dexmedetomidine, but not midazolam, prolongs

- bupivacaine spinal anesthesia. *Can J Anaes*. 2010;57:39–45.
13. Hall JE, Uhrich TD, Barney JA, Arain SR, Ebert TJ. Sedative, amnestic, and analgesic properties of small-dose dexmedetomidine infusions. *Anesth Analg*. 2000;90(3):699–705.
14. Scheinin H, Karhuvaara S, Olkkola KT. Pharmacodynamics and pharmacokinetics of intramuscular dexmedetomidine. *Clin Pharmacol Ther*. 1992;52:537–46.
15. Talke P, Tayefeh F, Sessler DI, Jeffrey R, Noursalehi M, Richardson C. Dexmedetomidine does not alter the sweating threshold, but comparably and linearly decreases the vasoconstriction and shivering thresholds. *Anesthesiology*. 1997;87:835–41.
16. Venn RM, Bradshaw CJ, Spencer R. Preliminary UK experience of dexmedetomidine, a novel agent for postoperative sedation in the intensive care unit. *Anaesthesia*. 1999;54:1136–42.

Author biography

Nishit Sud, Anaesthetic/ Intensive Care Registrar

Sunil Sinha, Director, Professor

Cite this article: Sud N, Sinha S. Perioperative effect of dexmedetomidine on quality of analgesia and hemodynamic parameters in vaginal hysterectomy: A tertiary centre experience. *Indian J Clin Anaesth* 2021;8(4):561-566.